Publication Type : Journal Article
Publisher : PMC
Source : Asian Pacific Journal of Cancer Prevention
Url : https://pmc.ncbi.nlm.nih.gov/articles/PMC5697457/
Campus : Faridabad
School : School of Medicine
Year : 2017
Abstract : Imatinib mesylate is approved for the treatment of Chronic Myeloid Leukemia (CML). About 20% of patients with CML do not respond to treatment with Imatinib either initially or because of acquired resistance. In addition to mutated BCR-ABL1 kinase, the organic cation transporter1 (OCT1, encoded by SLC22A1) has been considered to contribute to Imatinib resistance in patients with chronic myeloid leukemia (CML). OCT1 has been reported to be the main influx transporter involved in Imatinib uptake into CML cells. To date, only a few studies have been reported on involvement of influx transporters in development of Imatinib resistance. Therefore this study was aimed to determine the expression level of Imatinib uptake transporter (OCT1) in CML patients and to correlate this level with molecular response.
Cite this Research Publication : Chhikara, Sunita, Sudha Sazawal, Tulika Seth, Rekha Chaubey, Kanwaljeet Singh, Rahul Sharma, Pravas Mishra, Manaranjan Mahapatra, and Renu Saxena. "Molecular response to imatinib and its correlation with mRNA expression levels of imatinib influx transporter (oct1) in Indian chronic myeloid leukemia patients." Asian Pacific Journal of Cancer Prevention: APJCP 18, no. 8 (2017): 2043.